Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations

Korábbi kezelés

• No curative-intent therapy received (e.g., palliative treatment only).
• Patients with recurrence or who die within the first 5 months after starting curative-intent therapy (insufficient window for guideline-defined surveillance).

Más betegség

• Histology other than NSCLC, including:
  • Small-cell lung cancer Carcinoid tumors Rare non-NSCLC primary tumors
• Metastatic disease (stage IV) at diagnosis.
• Patients with missing identifiers prevent linkage to cancer registries or the death index.

Egyéb

• Patients with incomplete treatment records prevent the determination of the treatment completion date.
• Patients with no surveillance-relevant follow-up data, including:
  • No post-treatment clinical notes No radiology/pathology records No linked tumor registry or vital status data
• Individuals whose imaging cannot be classified as surveillance vs. diagnostic due to the absence of relevant structured or unstructured data.

• Adults diagnosed with primary, pathologically confirmed stage I-IIIA non- small cell lung cancer (NSCLC).
• Received curative-intent therapy, including:
  • Surgical resection, or Stereotactic body radiation therapy (SBRT), with or without adjuvant therapy.
• Completed curative-intent therapy and survived at least 5 months after therapy initiation.
• Received care within the University of Florida (Gainesville or Jacksonville) health system, and are included in the OneFlorida+ clinical data network.
• Have available:
  • Structured EHR data (including tumor registry linkage, imaging, procedures, and vital statistics), and Unstructured clinical documents (clinic notes, radiology reports, pathology reports) enable NLP extraction.
  • \- Have ≥1 follow-up encounter in the EHR after treatment completion to allow surveillance assessment.